Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 5/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | KLK7 | P49862 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3852558 | 0.93 | KMT2A (0.54) | KMT2AMEN1SMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL3852327 | 0.86 | HPGD (0.54) | KMT2AMEN1SMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL3851575 | 0.84 | KMT2A (0.67) | KMT2AMEN1SMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL4143779 | 0.80 | MEN1 (0.59) | KMT2AMEN1SMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL3855189 | 0.79 | MEN1 (0.49) | KMT2AMEN1SMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL3860317 | 0.79 | ALDH1A1 (0.46) | KMT2AMEN1SMN1; SMN2HPGDGAA | |
| SCHEMBL3850328 | 0.78 | MEN1 (0.76) | KMT2AMEN1SMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL3860282 | 0.78 | KMT2A (0.44) | KMT2AMEN1SMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL3853310 | 0.77 | KMT2A (0.43) | KMT2AMEN1SMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL4145804 | 0.76 | MEN1 (0.52) | KMT2AMEN1SMN1; SMN2HSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082368-A1 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082368-A1 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | NGF, BDNF, NTRK2 | KMT2A 4267/4885MEN1 3865/4885SMN1; SMN2 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.